Making antisense of splicing

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 5, 2005, Pages 476-482

  Garcia Blanco, Mariano A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alternative splicing; Dystrophin; Oligonucleotides; Pre mRNAs; Splice sites; Splicing

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLOOXYGENASE 1; DYSTROPHIN; FOMIVIRSEN; HEMOGLOBIN A; INTERFERON; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIBONUCLEASE H; SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID;

ALTERNATIVE RNA SPLICING; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; EXON; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; REVIEW; RNA INTERFERENCE; RNA SPLICING; SPINAL MUSCULAR ATROPHY;

ALTERNATIVE SPLICING; DYSTROPHIN; GENETIC DISEASES, INBORN; HUMANS; MUTATION; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS; RNA SPLICE SITES; RNA SPLICING; RNA, MESSENGER; THIONUCLEOTIDES;

EID: 27144442421     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem (2003) 72:291-336.
2. Caceres JF, Kornblihtt AR: Alternative splicing: Multiple control mechanisms and involvement in human disease. Trends Genet (2002) 18(4):186-193.
3. Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding nonsense: Exonic mutations that affect splicing. Nat Rev Genet (2002) 3(4):285-298.
4. Faustino NA, Cooper TA: Pre-mRNA splicing and human disease. Genes Dev (2003) 17(4):419-437.
5. Musunuru K: Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc Med (2003) 13(5):188-195.
6. Roca X, Sachidanandam R, Krainer AR: Intrinsic differences between authentic and cryptic 5′ splice sites. Nucleic Acids Res (2003) 31(21):6321-6333.
7. Garcia-Blanco MA, Baraniak AP, Lasda EL: Alternative splicing in disease and therapy. Nat Biotechnol (2004) 22(5):535-546.
8. Modrek B, Lee CJ: Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet (2003) 34(2):177-180.
9. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD: Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science (2003) 302(5653):2141-2144.
10. Sorek R, Shamir R, Ast G: How prevalent is functional alternative splicing in the human genome? Trends Genet (2004) 20(2):68-71.
11. Resch A, Xing Y, Alekseyenko A, Modrek B, Lee C: Evidence for a subpopulation of conserved alternative splicing events under selection pressure for protein reading frame preservation. Nucleic Acids Res (2004) 32(4):1261-1269.
12. Human Gene Mutation Database. HGMD, Cardiff, UK (2005): January 19. http://www.hgmd.org/
13. Ryther RC, McGuinness LM, Phillips JA 3rd, Moseley CT, Magoulas CB, Robinson IC, Patton JG: Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. Hum Genet (2003) 113(2):140-148.
14. Millar DS, Lewis MD, Horan M, Newsway V, Easter TE, Gregory JW, Fryklund L, Norin M, Crowne EC, Davies SJ, Edwards P et al: Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Hum Mutat (2003) 21(4):424-440.
15. Gunthert U, Stauder R, Mayer B, Terpe HJ, Finke L, Friedrichs K: Are CD44 variant isoforms involved in human tumour progression? Cancer Surv (1995) 24:19-42.
16. Venables JP: Aberrant and alternative splicing in cancer. Cancer Res (2004) 64(21):7647-7654.
17. Daoud R, Mies G, Smialowska A, Olah L, Hossmann KA, Stamm S: Ischemia induces a translocation of the splicing factor tra2-β1 and changes alternative splicing patterns in the brain. J Neurosci (2002) 22(14):5889-5899.
18. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol (1993) 13(8):4513-4522.
19. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA: Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene (1997) 15(25):3059-3065.
20. Yasumoto H, Matsubara A, Mutaguchi K, Usui T, McKeehan WL: Restoration of fibroblast growth factor receptor 2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate (2004) 61(3):236-242.
21. Bracco L, Kearsey J: The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol (2003) 21(8):346-353.
22. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-II variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA (2002) 99(21):13926-13931.
23. Simmons DL: Variants of cyclooxygenass-1 and their roles in medicine. Thromb Res (2003) 110(5-6):265-268.
24. Helmken C, Hofmann Y, Schoenen F, Oprea G, Raschke H, Rudnik-Schoneborn S, Zerres K, Wirth B: Evidence for a modifying pathway in SMA discordant families: Reduced SMN level decreases the amount of its interacting partners and Htra2-β1. Hum Genet (2003) 114(1):11-21.
25. Lorson CL, Hahnen E, Androphy EJ, Wirth B: A single nuclootide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA (1999) 96(11):6307-6311.
26. Kashima T, Manley JL: A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet (2003) 34(4):460-463.
27. Singh NN, Androphy EJ, Singh RN: An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem Biophys Res Commun (2004) 316(2):381-388.
28. Baron-Delage S, Abadie A, Echaniz-Laguna A, Melki J, Beretta L: Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med (2000) 6(11):957-968.
29. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B: Valproic acid increases the SMN2 protein level: A well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet (2003) 12(19):2481-2489.
30. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA (2001) 98(17):9808-9813.
31. Larsen AK, Escargueil AE, Skladanowski A: Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther (2003) 99(2):167-181.
32. Andreassi C, Jarecki J, Zhou J, Coovert DD, Monani UR, Chen X, Whitney M, Pollok B, Zhang M, Androphy E, Burghes AH: Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet (2001) 10(24):2841-2849.
33. Crooke ST: Antisense strategies. Curr Mol Med (2004) 4(5):465-487.
34. Crooke ST: Progress in antisense technology. Annu Rev Med (2004) 55:61-95.
35. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (1978) 75(1):280-284.
36. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA (1978) 75(1):285-288.
37. Vitravene Study Group: A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol (2002) 133(4):467-474.
38. Dominski Z, Kole R: Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA (1993) 90(18):8673-8677.
39. Sierakowska H, Sambade MJ, Agrawal S, Kole R: Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA (1996) 93(23):12840-12844.
40. Sazani P, Astriab-Fischer A, Kole R: Effects of base modifications on antisense properties of 2′-O-methoxyethyl and PNA oligonucleotides. Antisense Nucleic Acid Drug Dev (2003) 13(3):119-128.
41. Kole R, Vacek M, Williams T: Modification of alternative splicing by antisense therapeutics. Oligonucleotides (2004) 14(1):65-74.
42. Kole R, Williams T, Cohen L: RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim Pol (2004) 51(2):373-378.
43. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, Kole R: Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA (2000) 97(17):9591-9596.
44. Vacek M, Sazani P, Kole R: Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci (2003) 60(5):825-833.
45. Gorman L, Suter D, Emerick V, Schumperli D, Kole R: Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA (1998) 95(9):4929-4934.
46. Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R: Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem (1999) 274(51):36193-36199.
47. Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M: Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun (1996) 226(2):445-449.
48. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G: Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet (1998) 7(7):1083-1090.
49. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, Kole R: Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord (1999) 9(5):330-338.
50. De Angelis FG, Sthandier O, Berarducci B, Toso S, Galluzzi G, Ricci E, Cossu G, Bozzoni I: Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ48-50 DMD cells. Proc Natl Acad Sci USA (2002) 99(14):9456-9461.
51. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schumperli D: Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res (2004) 32(12):3752-3759.
52. s through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol (1999) 17(11):1097-1100.
53. Karras JG, Maier MA, Lu T, Watt A, Manoharan M: Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-α chain. Biochemistry (2001) 40(26):7853-7859.
54. Kalbfuss B, Mabon SA, Misteli T: Correction of alternative splicing of τ in frontotemporal dementia and Parkinsonism linked to chromosome 17. J Biol Chem (2001) 276(46):42986-42993.
55. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Levy N: Lamin a truncation in Hutchinson-Gilford progeria. Science (2003) 300(5628):2055.
56. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A et al: Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature (2003) 423(6937):293-298.
57. Scaffidi P, Misteli T: Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med (2005) 11(4):440-445.
58. Takeshima Y, Wada H, Yagi M, Ishikawa Y, Ishikawa Y, Minami R, Nakamura H, Matsuo, M: Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev (2001) 23(8):788-790.
59. Bruno IG, Jin W, Cote GJ: Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet (2004) 13(20):2409-2420.
60. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R: Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 20(12):1228-1233.
61. Muntoni F, Torelli S, Ferlini A: Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol (2003) 2(12):731-740.
62. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC: Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet (2004) 74(1):83-92.
63. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ: The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science (1989) 244(4912):1578-1580.
64. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD: Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA (2001) 98(1):42-47.
65. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD: Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med (2003) 9(8):1009-1014.
66. Wells KE, Fletcher S, Mann CJ, Wilton SD, Wells DJ: Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett (2003) 552(2-3):145-149.
67. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O: Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science (2004) 306(5702):1796-1799.
68. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA (2005) 102(1):198-203.
69. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH, van Ommen GJ, den Dunnen JT, van Deutekom JC: Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther (2004) 10(2):232-240.
70. Villemaire J, Dion I, Elela SA, Chabot B: Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J Biol Chem (2003) 278(50):50031-50039.
71. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA (2003) 100(7):4114-4119.
72. Cartegni L, Krainer AR: Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol (2003) 10(2):120-125.
73. Eperon IC, Muntoni F: Response to Buratti et al: Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better? Trends Mol Med (2003) 9(6):233-234.
74. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell JR, Coulson SE, Androphy EJ, Prior TW, Burghes AH: The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 6(8):1205-1214.
75. Buratti E, Baralle FE, Pagani F: Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better? Trends Mol Med (2003) 9(6):229-232.
76. Khoo B, Akker SA, Chew SL: Putting some spine into alternative splicing. Trends Biotechnol (2003) 21(8):328-330.
77. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ: Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med (2003) 9(12):1539-1544.
78. Dykxhoom DM, Novina CD, Sharp PA: Killing the messenger: Short RNAs that silence gene expression. Nat Rev Mol Cell Biol (2003) 4(6):457-467.
79. Wall NR, Shi Y: Small RNA: Can RNA interference be exploited for therapy? Lancet (2003) 362(9393):1401-1403.
80. Stevenson M: Therapeutic potential of RNA interference. N Engl J Med (2004) 351(17):1772-1777.
81. Celotto AM, Graveley BR: Exon-specific RNAi: A tool for dissecting the functional relevance of alternative splicing. RNA (2002) 8(6):718-724.
82. Garcia-Blanco MA: Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J Clin Invest (2003) 112(4):474-480.